Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $77 |
| Triangulated Fair Value | $71 |
| 12-mo Scenario PWEV | $79 |
| Implied Return | -7% |
| Forward P/E | 11.8x |
| Market Cap | $13B |
| 52-Week Range | $62 – $88 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $139, +80% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($77) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) — targets $35, -55% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 50% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.60 vs analyst floor +0.00 → delta +0.60 (n=26 mgmt / 14 Q&A; 88th pctile across the S&P book, z +1.3).
Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.60 | +0.00 | +0.60 |
| 2025Q4 | +0.40 | +0.19 | +0.21 |
| 2025Q3 | +0.47 | +0.00 | +0.47 |
| 2025Q2 | +0.46 | +0.43 | +0.03 |
News (last 365d, 590 articles): avg ticker sentiment +0.17 (bullish 25% / bearish 7%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($35) to a 'Bull — Re-Rate' bull case ($139); the probability-weighted blend (PWEV $79) is +2% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | 20% | $35 | -55% |
| Hospital-Capex / Utilization Recession | 17% | $59 | -24% |
| Base — Procedure Volume + Innovation | 35% | $82 | +6% |
| Growth — New-Product Cycle / Penetration | 20% | $110 | +43% |
| Bull — Re-Rate | 8% | $139 | +80% |
| Probability-Weighted (PWEV) | — | $79 | +2% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $35). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 34.58; probability: 0.2.
- Hospital-Capex / Utilization Recession (17%, $59). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 58.73; probability: 0.17.
- Base — Procedure Volume + Innovation (35%, $82). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 81.57; probability: 0.35.
- Growth — New-Product Cycle / Penetration (20%, $110). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 110.12; probability: 0.2.
- Bull — Re-Rate (8%, $139). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 139.08; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $70 | -9% |
| Peer P/E re-rate | multiple | $100 | +30% |
| Peer EV/Revenue re-rate | multiple | $133 | +73% |
| Scenario PWEV | multiple | $79 | +2% |
| DCF (5-year + terminal) | cash flow + terminal × | $59 | -24% |
| Triangulated (weighted) | — | $71 | -7% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $70 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (50% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 10x terminal FCF multiple → $59. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.295000000000002x) implies $100. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Medical Devices & Equipment | $8.3B | 100% | 6% | 16% | 12x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | procedure volumes + product-innovation cycle + hospital capital spending |
| net_debt_or_cash_b | -4.52 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / competition / GLP-1 procedure hit |
| upside | new-product cycle + penetration |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $9B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $9B | $2B | $0B | $0B | $1B | $1B |
| FY+3 | $10B | $2B | $0B | $0B | $1B | $1B |
| FY+4 | $10B | $2B | $1B | $0B | $1B | $1B |
| FY+5 | $10B | $2B | $1B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 10x | $10B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $10B = EV $15B; + net cash → equity $10B ÷ diluted shares 0.17B = $59/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $98/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 12% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| VEEV | 5.56x | 17.57x | 6% | 31% |
| COO | 3.807x | 15.13x | 6% | -3% |
| DVA | 1.897x | 14.71x | 4% | 14% |
| ALGN | 2.842x | 15.46x | 6% | 17% |
| Median | 3.3245x | 15.295000000000002x | — | — |
Peer-median fwd P/E → $100; EV/Rev → $133.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $59 | 41% | $24 |
| Scenario PWEV | $79 | 29% | $23 |
| Monte Carlo median | $70 | 18% | $12 |
| Peer P/E | $100 | 12% | $12 |
| Triangulated | — | 100% | $71 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 7.0x | 8.5x | 10.0x | 11.5x | 13.0x |
|---|---|---|---|---|---|
| 6% | $48 | $57 | $66 | $75 | $84 |
| 8% | $45 | $54 | $62 | $71 | $80 |
| 8% | $42 | $50 | $59 | $67 | $75 |
| 10% | $40 | $48 | $55 | $63 | $71 |
| 10% | $37 | $45 | $52 | $60 | $67 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $37 | $43 | $50 | $57 | $64 |
| -1.5pp | $40 | $47 | $54 | $62 | $69 |
| +0.0pp | $43 | $51 | $59 | $67 | $74 |
| +1.5pp | $47 | $55 | $63 | $72 | $80 |
| +3.0pp | $50 | $59 | $68 | $77 | $86 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $43 | $74 | $31 |
| Revenue CAGR ±3pp | $50 | $68 | $18 |
| Terminal × ±15% | $50 | $67 | $17 |
| WACC ±1pp | $55 | $62 | $7 |
| FCF conversion ±10% | $59 | $59 | $0 |
Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 12x)
| Multiple | 8.4x | 10.2x | 12.0x | 13.8x | 15.6x |
|---|---|---|---|---|---|
| SoP/share | $377 | $463 | $550 | $636 | $722 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 10×, FY+5 revenue $10B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $35.
Fact / Inference / Speculation
- FACT: Spot $77; 52-week range $62–$88; engine rating HOLD; base-case target $79 (+2%).
- INFERENCE: Triangulated FV $71 (-7%). Gross Margin explains 50% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 50% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $71 (-7% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (50% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).